Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
Employees: 51-200
Total raised: $70.01M
Founded date: 2011
Investors 3
Funding Rounds 4
| Date | Series | Amount | Investors |
| 08.12.2022 | - | $23M | - |
| 05.10.2020 | - | $22.01M | - |
| 18.03.2020 | Grant | $5M | - |
| 10.02.2015 | Series B | $20M | - |
Mentions in press and media 18
| Date | Title | Description | Source |
| 06.06.2023 | Vaxxas Announces Interim Phase I Study Results for First Nee... | Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today a... | brandoncap... |
| 19.01.2023 | Coming in from the cold: needle-free patch technology for mR... | CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas , a clinical-stage biotechnolo... | brandoncap... |
| 06.12.2022 | Vaxxas Raises US$23 million (A$34 million) to Clinically Adv... | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today a... | brandoncap... |
| 05.12.2022 | Vaxxas Raises US$23M in Funding | Vaxxas, a Cambridge, MA- and Brisbane, Australia-based clinical-stage biotechnology company, raised ... | finsmes.co... |
| 05.12.2022 | Vaxxas Raises $23M for Needle-Free Vaccine Tech Jobs at Vax... | Vaxxas’ needle-free vaccine patch. | Photo: Vaxxas / LinkedIn Trypanophobia, the fear of needles an... | builtinbos... |
| 20.09.2022 | Vaxxas receives more than $5 million grant for vaccine deliv... | Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]V... | massdevice... |
| 03.06.2021 | Preclinical studies from Vaxxas and Collaborators Reveal Pot... | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today a... | brandoncap... |
| 05.10.2020 | Vaxxas Announces US$22 Million (A$30.6 Million) Award from U... | Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today... | brandoncap... |
| 18.03.2020 | Vaxxas Awarded US$5 million Grant for Clinical Study of Meas... | Vaxxas, a biotechnology company commercializing a novel vaccination platform, today announced that i... | brandoncap... |
| 16.03.2015 | Intergenerational prosperity depends on supporting research | According to the Intergenerational Report (IGR) released earlier this month, Australia’s future prod... | smartcompa... |
Show more